EGFR and colorectal cancer: Recent data on colorectal cancer suggested that one of the molecular mechanisms responsible of primary and acquired resistance to anti-EGFR therapies is the activation of MEK/MAPK [18–20] and that the simultaneous inhibition of EGFR and MEK/MAPK could overcome this resistance.